top of page
  • Recruiting

NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

Updated: Feb 5


  • NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

iberdomide

This is a phase II study to determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-ASCT. Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle. Treatment will continue until disease progression or toxicity. A maximum of 38 subjects will be enrolled. The results from this study will inform the feasibility of pursuing a phase 3 study comparing iberdomide to lenalidomide maintenance post-ASCT.


Sponsor

University of Nebraska

 

ClinicalTrials.gov Identifier: NCT05177536

Official Title: Phase 2 Study of Iberdomide Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma

First Posted : January 4, 2022


Click here to see details on ClinicalTrials.gov

 
 

Drug: Iberdomide

 

Location

United States, Nebraska

Comments


Posts Archive
bottom of page